Radiopharm Theranostics Limited (AU:RAD) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Radiopharm Theranostics has successfully completed preclinical studies for its innovative prostate cancer treatment, RAD 402, showing promising safety and biodistribution results. The company plans to begin Phase I clinical trials in the second half of 2025, aiming to advance this next-generation radiotherapeutic to address unmet needs in advanced prostate cancer. This development signifies a potential breakthrough in cancer treatment, with RAD 402 targeting prostate-specific antigens using the novel isotope Terbium-161.
For further insights into AU:RAD stock, check out TipRanks’ Stock Analysis page.